Ladenburg analyst Aydin Huseynov raised the firm’s price target on Compass Therapeutics (CMPX) to $7 from $5 and keeps a Buy rating on the shares post the Q3 report. The firm notes growing optimism around CTX-009.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter